The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

By Akin Nazli in Belgrade Ugur Sahin, owner of BioNTech (Nasdaq/BNTX), has been ranked second in Forbes Turkey’s Top 100 ...

Clinical trials are the cornerstone of medical innovation, offering a rigorous framework to evaluate the safety and ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

Health-care companies ticked down amid mixed fortunes for the sector. BioCryst Pharmaceuticals shares surged after the biotech firm said it would turn a profit in 2025, a year earlier than anticipated ...

Democratic-led states challenge Trump's gutting of health agencies. Tyson Foods eliminates synthetic dyes. Trump to sign ...

BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

German drugmaker BioNTech reported Monday wider net loss in its first quarter with weak revenues. Further, the company ...